Organization & Developments: CureVac

Parents

CureVac N.V. (Nasdaq: CVAC)*

Children

*CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases.
*Germany-based biotechnology company focused on the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines
*Next-gen mRNA vaccines leveraging AI for rapid design and optimization.
2017: Eli Lilly is putting up $1.8 billion (€1.5 billion) to work with CureVac on five mRNA cancer vaccines.
2017: Lilly, CureVac pen $1.8 B mRNA cancer vaccine deal
2020: CureVac gets OK to start testing mRNA COVID-19 vaccine in humans
2020: CureVac's mRNA coronavirus shot boasts one advantage over Pfizer and Moderna counterparts—refrigerated storage
2020: GSK, Germany push coronavirus-focused mRNA player CureVac’s latest round to $640M – Endpoints News
2020: Tesla chief Elon Musk teams up with Covid-19 player CureVac to build ‘RNA microfactories’ – Endpoints News
2021: CureVac blames variants as a closely-watched Covid vaccine goes down in flames, failing pivotal study with woeful data
2021: CureVac: Last Call For Investors Before Likely Positive COVID Vaccine Data Drops
2021: CureVac: Smart Money Is On COVID-19 Vaccine Approval
2021: GSK and CureVac Take Aim at COVID-19 Variants with Second-Generation mRNA Vaccine
2021: JPM: CureVac's new pharma partner Bayer says its COVID-19 vaccine not just an also-ran
2022: CureVac N.V. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: CureVac turns to next-generation mRNA tech After failed COVID vaccine
2022: CureVac: No Sign Of Momentum For This Biotech Stock_ seekingalpha.com
2022: CureVac's 'half-baked' COVID-flu data release questioned by analysts, but shares still rally 17%
2023: CureVac: Failing To Live Up To Its Initial Hype_ seekingalpha.com
2024: CureVac cuts jobs, licenses out vaccines to GSK
2024: CureVac: Back To Square One

Jumps

*Key People: CureVac
Finance & Acquisitions: CureVac

Made with TheBrain